ADVERTISEMENT

Conference Report

ESMO 2022 – Moving beyond chemotherapy in unfit lung cancer patients

Cristina Ferrario — Agenzia Zoe   |   12 September 2022

Takeaway

  • First-line immunotherapy with atezolizumab led to significant survival benefits compared to chemotherapy in unfit patients with advanced/metastatic non-small-cell lung cancer (NSCLC) who were ineligible for platinum-based regimens.
  • Benefits were independent of PD-L1 status, performance status, and histology.
  • QoL was maintained and no new safety signals emerged.

Why this matters...

          

November Challenge

Ends in 1d 5h
left
right

Topic Challenges

left
right